Top Markets
#1 MowCat MowCat +779.10%
#2 龙虾 (Lobster) 龙虾 (Lobster) +84.18%
#3 Magma Finance Magma Finance +38.31%
#4 Akedo Akedo +38.00%
#5 MarsCoin MarsCoin +31.11%
#6 SIXSEVEN SIXSEVEN +30.85%
#7 Cortex Cortex +25.84%
#8 DeXe DeXe +19.90%
#9 Pons Pons +15.98%
#10 OpenEden OpenEden +14.56%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Harrow Health, Inc. 8.625% Senior Notes due 2026 Harrow Health, Inc. 8.625% Senior Notes due 2026

Harrow Health, Inc. 8.625% Senior Notes due 2026

HROWL
Rank in Stocks #8090
Harrow, Inc. is a pharmaceutical company that specializes in the development,... Harrow, Inc. is a pharmaceutical company that specializes in the development, production, and distribution of innovative medications. Its business activities are primarily divided into two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding division notably encompasses the operations of the ImprimisRx business. Co-founded by Mark L. Baum and Robert J. Kammer in January 2006, the firm maintains its corporate headquarters in Nashville, Tennessee.
Share Price
$25.61
Last synced: 2025-10-10
Market Cap
$1.37B
Change (1 day)
0.20%
Change (1 year)
1.59%
Country
US
Trade Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)

Category

Healthcare
P/E ratio for Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)
P/E ratio as of 2026 TTM: 0
According to Harrow Health, Inc. 8.625% Senior Notes due 2026 latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Harrow Health, Inc. 8.625% Senior Notes due 2026 from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 24.32 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 31.46 -
HK
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.